Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.

Guide · Weight loss · United States

Peptides for weight loss: which are approved, what the trials show, and what they cost

The peptides with FDA approval for weight management, and the largest published trials, are the GLP-1 medicines semaglutide (Wegovy) and tirzepatide (Zepbound).[1][3] Several newer peptides, such as retatrutide, CagriSema and survodutide, are still in trials. Others marketed for fat loss, such as AOD-9604 and MOTS-c, have no FDA approval for it. This guide sets out the status of each, what the trials reported, and what the approved options cost today.

Weight loss peptides at a glance

Peptides used or researched for weight loss, with FDA status and US availability
MedicineWhat it isFDA status for weight lossCan you get it in the US?
Semaglutide (Wegovy)GLP-1 receptor agonist, a peptide. Weekly injection or daily pillFDA approved for chronic weight management: injection June 4, 2021; pill December 22, 2025[1][2][16]Yes, on prescription: brand-name Wegovy, or compounded semaglutide (compounded medicines are not FDA approved)
Tirzepatide (Zepbound)GLP-1 and GIP receptor agonist, a peptide. Weekly injectionFDA approved for chronic weight management, November 8, 2023[3][16]Yes, on prescription: brand-name Zepbound, or compounded tirzepatide (not FDA approved)
Liraglutide (Saxenda)GLP-1 receptor agonist, a peptide. Daily injectionFDA approved for obesity, December 23, 2014[4]Yes, on prescription
Orforglipron (Foundayo)Not a peptide: Lilly describes it as a small molecule (non-peptide) GLP-1 receptor agonist. Daily pillFDA approved for weight reduction and maintenance, April 1, 2026[6][5]Yes, on prescription
RetatrutideGIP, GLP-1 and glucagon receptor agonist, a peptide. Weekly injectionInvestigational. Not approved for any use; Lilly plans to file with the FDA in Q1 2027[10][15]No. Products sold online as "research" retatrutide are unapproved drugs
CagriSema (cagrilintide and semaglutide)An amylin analog combined with semaglutide. Weekly injectionNot FDA approved. Novo Nordisk announced its New Drug Application on December 18, 2025[11]No, outside clinical trials
SurvodutideGLP-1 and glucagon receptor agonist, a peptide. Weekly injectionInvestigational, in Phase 3 trials. Not approved[12]No, outside clinical trials
Tesamorelin (Egrifta)Growth hormone releasing hormone analog, a peptideFDA approved in 2010 only to reduce excess abdominal fat in adults with HIV and lipodystrophy. Not approved for general weight loss[13]On prescription for its approved use
MOTS-cA mitochondrial peptide researched for metabolismNot FDA approved for any use. One of six peptides in the HHS interim compounding policy of October 30, 2026, which is not an approval[14]Only as a compounded product under that interim policy, on prescription
AOD-9604A fragment of human growth hormone marketed for fat lossNot FDA approved for any use, and not in the HHS interim compounding policy[14]No approved or policy-covered route

What the trials reported

These are the headline results each source reports. The trials enrolled different people for different lengths of time, so the figures cannot be compared as if the medicines were tested against each other.

  • Semaglutide 2.4 mg (STEP 1, 1,961 adults, 68 weeks): Average weight change about minus 14.9%, against minus 2.4% with placebo.[7]
  • Tirzepatide, highest dose (SURMOUNT-1, 72 weeks): Average weight loss 20.9%, against 3.1% with placebo.[8]
  • Retatrutide, highest dose (investigational) (TRIUMPH-1, 80 weeks): Average weight loss 25.0%, against 3.9% with placebo (treatment-regimen estimand).[9]
  • Survodutide (investigational) (SYNCHRONIZE-1, 76 weeks): Up to 16.6% average weight loss, against 3.2% with placebo.[12]

Non-prescription and “research” peptides

No FDA-approved weight loss peptide is sold without a prescription. Peptides sold online “for research use”, including retatrutide and semaglutide, are unapproved drugs, and the FDA has warned sellers of them.[15][16] The HHS compounding policy of October 30, 2026 covers six peptides, including MOTS-c, for compounding on a prescription; it is not an FDA approval and it does not cover retatrutide, semaglutide research products or AOD-9604.[14] For what that policy does cover, see how BPC-157 and the other five peptides can be prescribed.

What weight loss peptides cost

  • Wegovy, brand name: $149 a month for the pill and $199 a month for the pen at NovoCare Pharmacy, Novo Nordisk's own self-pay pharmacy (checked November 19, 2026). See Wegovy cost without insurance.
  • Zepbound, brand name: from $299 a month at LillyDirect, Lilly's own self-pay pharmacy (checked November 19, 2026). See Zepbound cost without insurance.
  • Compounded tirzepatide: $69 to $399 a month on a month to month plan across 13 US online programs (checked November 19, 2026).
  • Compounded semaglutide: the lowest price we track is $39 a month for compounded semaglutide at welludr, an advertised sale price, checked November 19, 2026.

The table below lists every compounded GLP-1 price we track, read daily from each provider's own page and dated. A prescription is a clinician's decision after an online review, never guaranteed.

#ProviderPriceWhat the price isCurrent offerCheckedLink
1
welludr logo
welludrsemaglutide
$39/moStarting at, advertised sale price, per monthPage wording: BLACK FRIDAY SALE DISCOUNT APPLIED $39 /mo Semaglutide $69 /mo TirzepatideNew Customer Offer: $150 off for LifeOffer end date not statedSee pricing
2
Embody logo
Embodysemaglutide
$49/moadvertised sale price, per monthPage wording: PRE-BLACK FRIDAY SALE DISCOUNT APPLIED! $49 Semaglutide / $99 TirzepatidePRE-BLACK FRIDAY SALE DISCOUNT APPLIED!Standard price Was $299Sale end recorded: Nov 24See pricing
3
REBL logo
REBLsemaglutide
$55/moFrom, ongoing monthly pricePage wording: Treatments from $55/moNone recorded
4
Collective logo
Collectivesemaglutide
$59/moongoing monthly price; plus a required $199 annual membershipPage wording: Compounded Semaglutide $59/mo. Same price, any dose.None recordedSee pricing
5
SnagRx logo
SnagRxsemaglutide
$59/moadvertised sale price, per monthPage wording: PRE-BLACK FRIDAY SALE DISCOUNT APPLIED! Semaglutide for $59 / Tirzepatide for $109PRE-BLACK FRIDAY SALE DISCOUNT APPLIED!Standard price Was $299Sale end recorded: Nov 24See pricing
6
Arbor logo
Arborsemaglutide
$89/moFrom, ongoing monthly pricePage wording: Semaglutide From $89/moNone recordedSee pricing
7
Yucca Health logo
Yucca Healthsemaglutide
$89/moFrom, ongoing monthly pricePage wording: Monthly Plan Billed monthly · no commitment $89 /mo was $146/moNone recordedPaused: not currently accepting new patients through our links. See alternatives
8
bmiMD logo
bmiMDsemaglutide
$99/moStarting as low as, ongoing monthly pricePage wording: Compounded Semaglutide Starting as low as $99/moNone recordedSee pricing
9
Eden Health logo
Eden Healthsemaglutide
$99/moongoing monthly pricePage wording: Semaglutide $99 /moNone recordedSee pricing
10
GobyMeds logo
GobyMedssemaglutide
$99/moStarting at, per month on a prepaid plan: 3-month starter bundle, $299 billedPage wording: Starting at $99/m Compounded Semaglutide 3-Month Starter Bundle ... Total $299None recordedSee pricing
11
Trimi logo
Trimisemaglutide
$99/moper month on a prepaid plan: 12-month plan, $1,188 billedPage wording: 12 months Lowest rate $99/mo $1,188 billed upfrontNone recordedPaused: not currently accepting new patients through our links. See alternatives
12
Strut Health logo
Strut Healthsemaglutide
$129/moongoing monthly pricePage wording: SEMAGLUTIDE INJECTABLE $129 Monthly vialNone recordedSee pricing
13
Healthy Living Clinic logo
Healthy Living Clinictirzepatide
$149price per 4 weeks for 3 mg to 9 mg a week; ships as a 12-week box paid in 3 payments, one every 4 weeks, and all 3 are due once the box shipsPage wording: Tirzepatide - Intermediate Dose $149.00 /4weeksNone recordedSee pricing
14
TMates logo
TMatessemaglutide
$158/moper month on a prepaid plan: 12 months, $1,900 billedPage wording: 12 Months$158/mo Save 37% $1900None recordedPaused: not currently accepting new patients through our links. See alternatives
15$159.33/moper month on a prepaid plan: 3-month bundle, $478 billedPage wording: $159.33/mo on 3-month bundleFirst month $179 (standard $279)Offer end date not statedSee pricing
16
MEDVi logo
MEDVitirzepatide
$166/moadvertised sale price, per monthPage wording: Friday Sale: Tirzepatide only $166/moFriday SaleOffer end date not statedSee pricing
17
MEDGm logo
MEDGmsemaglutide
$169/moper month on a prepaid plan: 12-Month Supply, $2,028 billedPage wording: 12-Month Supply Billed every 12 months $2,028 $169/moNone recordedSee pricing
18
Sprout Health logo
Sprout Healthsemaglutide
$169/moStarting at, ongoing monthly pricePage wording: Compounded semaglutide Starting at $169/moNone recordedSee pricing
19
Shed logo
Shedsemaglutide
$175/moStarting at, ongoing monthly pricePage wording: BLACK FRIDAY PRICE LOCKED FOREVER Compounded Semaglutide $175 /mo was $199 Billed as $350 every 2 monthsNone recordedSee pricing
20
Fridays logo
Fridaystirzepatide
$198/moAs low as, advertised sale price, per monthPage wording: Tirzepatide: As low as $198/moPRICE LOCKED IN FOREVEROffer end date not statedSee pricing
21
Luvo Health logo
Luvo Healthsemaglutide
$209price per 4 weeks, billed every 4 weeksPage wording: 4 weeks of injections, delivered every 4 weeks. $209 from your second delivery.None recordedSee pricing
22
PeterMD logo
PeterMDtirzepatide
$249/moongoing monthly pricePage wording: Then $249 per month • billed quarterly • 60mgNone recordedSee pricing
23
Found logo
Foundsemaglutide
$289/moongoing monthly pricePage wording: Compounded semaglutide 1 month $199/mo $289/moNone recordedSee pricing
24
Wellorithm logo
Wellorithmsemaglutide
$299/moongoing monthly pricePage wording: Compounded semaglutide ongoing (every month) $299First month $179Offer end date not statedSee pricing
Regulatory note: After the FDA declared the semaglutide shortage resolved in February 2025, pharmacies could no longer routinely compound copies of that licensed product. On May 1, 2026 the FDA published a notice proposing not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List; a final determination is still pending. The availability and pricing described here may not reflect what a provider can currently supply, so confirm the current offering and cost directly with any provider before relying on it.Last reviewed: July 2026

Source: FDA: Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) · United States · Decision February 21, 2025

Source: FDA: Federal Register notice — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B · United States · Published May 1, 2026

For every price in one place, see the US GLP-1 price index; to choose a program by what matters to you, see the best online GLP-1 programs by use case.

Frequently asked questions

What is the best peptide for weight loss?

There is no single best one for everyone; that is a decision for a licensed clinician. The peptides with FDA approval for weight management and the largest published trials are semaglutide (Wegovy) and tirzepatide (Zepbound), both GLP-1 medicines. Peptides such as AOD-9604 and MOTS-c are marketed for fat loss but have no FDA approval for it.

Are there non-prescription peptides for weight loss?

No FDA-approved weight loss peptide is sold without a prescription. Products sold online as "research" peptides, including retatrutide and semaglutide, are not approved medicines, and the FDA has issued warning letters to sellers of them.

Is semaglutide a peptide?

Yes. Semaglutide, tirzepatide and liraglutide are peptides. Orforglipron (Foundayo), Lilly's GLP-1 pill, is not: Lilly describes it as a small molecule, non-peptide medicine.

How much do weight loss peptides cost?

Brand-name Wegovy starts at $149 a month from Novo Nordisk's own pharmacy. Brand-name Zepbound starts at $299 a month from LillyDirect. Compounded tirzepatide costs $69 to $399 a month on a month to month plan across the US online programs we track. The lowest compounded semaglutide price is $39 a month for compounded semaglutide at welludr, an advertised sale price, checked November 19, 2026. Every figure is read from the seller's own page and dated; compounded medicines are not FDA approved.

Can I get retatrutide for weight loss?

No. Retatrutide is investigational and not approved for any use; Lilly plans to file with the FDA in the first quarter of 2027. The approved medicines in the same family that you can be prescribed today are tirzepatide and semaglutide.

For what the FDA has said about each peptide, see our guide are peptides safe.

Sources

Each numbered reference points to one of these. The date is the day we read the source; trial figures are quoted as the source reports them.

  1. FDA news release, June 4, 2021: FDA approves new drug treatment for chronic weight management, first since 2014 (Wegovy, semaglutide injection 2.4 mg once weekly), as republished by BioSpace. www.biospace.com. Read November 15, 2026.
  2. Drug Topics, December 23, 2025: Wegovy pill (oral semaglutide 25 mg) receives FDA approval for weight management (approved Monday, December 22, 2025). www.drugtopics.com. Read November 15, 2026.
  3. Drugs.com approval history: FDA approves Zepbound (tirzepatide) for chronic weight management, November 8, 2023. www.drugs.com. Read November 15, 2026.
  4. Drugs.com approval history: FDA approves Saxenda (liraglutide) for obesity, December 23, 2014. www.drugs.com. Read November 15, 2026.
  5. Eli Lilly press release, April 9, 2026: Foundayo (orforglipron), described as a once-daily small molecule (non-peptide) oral GLP-1 receptor agonist, available in the US. investor.lilly.com. Read November 15, 2026.
  6. Fierce Pharma: FDA approval of Foundayo (orforglipron), announced by the agency on April 1, 2026. www.fiercepharma.com. Read November 15, 2026.
  7. American College of Cardiology trial summary, STEP 1 (Wilding JPH et al., New England Journal of Medicine 2021): semaglutide 2.4 mg in 1,961 adults with overweight or obesity over 68 weeks. www.acc.org. Read November 15, 2026.
  8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine 2022. pubmed.ncbi.nlm.nih.gov. Read November 15, 2026.
  9. Eli Lilly press release, May 21, 2026: TRIUMPH-1 topline results for retatrutide. investor.lilly.com. Read November 15, 2026.
  10. Eli Lilly press release, July 23, 2026: TRIUMPH-2 and TRIUMPH-3 results, and the plan to file retatrutide with the FDA in Q1 2027. lilly.gcs-web.com. Read November 15, 2026.
  11. Drugs.com development history: CagriSema (cagrilintide and semaglutide), FDA approved: No; New Drug Application announced by Novo Nordisk on December 18, 2025. www.drugs.com. Read November 15, 2026.
  12. BioPharm International, April 28, 2026: survodutide (investigational) SYNCHRONIZE-1 Phase 3 results, up to 16.6% average weight loss against 3.2% with placebo over 76 weeks. www.biopharminternational.com. Read November 15, 2026.
  13. Drugs.com approval history: Egrifta (tesamorelin), first FDA approved November 10, 2010, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. www.drugs.com. Read November 15, 2026.
  14. HHS Office of the Secretary, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances", Docket No. HHS-OASH-2026-0496, Federal Register public inspection copy (published October 30, 2026). public-inspection.federalregister.gov. Read November 15, 2026.
  15. FDA warning letter to Prime Vitality, Inc. dba Prime Peptides, December 10, 2024: retatrutide and semaglutide sold online as "research" products are unapproved new drugs. www.fda.gov. Read November 15, 2026.
  16. FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss. www.fda.gov. Read November 15, 2026.

This page is information, not medical advice. It does not recommend any medicine and gives no dosing guidance. Talk to a licensed clinician about what is appropriate for you.